Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation

Anand P. Jillella, Martha L. Arellano, Leonard T. Heffner, Manila Gaddh, Amelia A. Langston, Hanna J. Khoury, Abhishek Mangoankar, Vamsi K. Kota

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Acute promyelocytic leukemia (APL) is a hyper-acute leukemia and presents with cytopenias and disseminated intravascular coagulation. Jehovah’s Witnesses with APL offer a unique challenge during induction by refusing transfusion and pose a difficult challenge in this curable disease. Our focus over the last 8 years has been decreasing early deaths in APL in both academic and community centers. As a result we have extensive experience in APL induction with a proven improvement in early deaths. Three patients with APL belonging to the Jehovah’s Witness congregation were treated in our practice and published literature in treating Witnesses with APL was reviewed. It is highly imperative to prevent induction mortality in this patient population. The goal of treatment among the Witnesses is to prevent death during induction and subsequently cure them. We discuss the management and proactive measures to prevent induction mortality in this most curable blood cancer.

Original languageEnglish (US)
Article number7083
Pages (from-to)102-105
Number of pages4
JournalHematology Reports
Volume9
Issue number3
DOIs
StatePublished - Sep 26 2017
Externally publishedYes

Keywords

  • Acute Promyelocytic leukemia
  • Early deaths
  • Jehovah Witness

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation'. Together they form a unique fingerprint.

  • Cite this

    Jillella, A. P., Arellano, M. L., Heffner, L. T., Gaddh, M., Langston, A. A., Khoury, H. J., Mangoankar, A., & Kota, V. K. (2017). Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation. Hematology Reports, 9(3), 102-105. [7083]. https://doi.org/10.4081/hr.2017.7083